Founder of GloboMax, Keith is currently a professor at the Graduate Institute of Intellectual Property, College of Commerce, National Chengchi University and adjunct professor and advisor at the Research Center for Drug Discovery, National Yang Ming University in Taipei, Taiwan. He also serves as Director of International Affairs, GloboAsia LLC and Revico Inc., Rockville, Maryland. He is an advisor for several research institutes and regulatory agencies in Asia, as well as a consultant for several pharmaceutical firms in Asia and in the U.S.

Previously, Keith co-founded GloboMax LLC, a drug development organization, in Hanover, Maryland, in 1997, and served as consultant for numerous multi-national pharmaceutical biotech firms in the U.S, Europe and Asia. GloboMax was acquired by ICON, plc. in 2003, and Keith exited  the operation. He has worked for the U.S. FDA as Division Director at the Office of Generic Drugs. He served as adjunct professor at the School of Pharmacy, University of Maryland in Baltimore, for many years, and also served as adjunct professor and on the National Board of Advisors, College of Pharmacy, University of Minnesota in Minneapolis, from 1984 on. Keith previously worked for Ciba-Geigy Corporation in Ardsley, New York, for 15 years, and held various senior and management positions. He has published more than 150 abstracts and research articles in peer-reviewed journals and over 200 professional presentations. He was elected as Fellow of the American Association of Pharmaceutical Scientists PSJ in 1995 for his scientific accomplishments on drug absorption in humans.

Although much of his career has been based in the United States, Keith has also assisted Asian pharmaceutical and biotech companies over the last 14 years. He has organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore and Korea. He lectures frequently in Asia and serves as a scientific advisor for many regulatory agencies in Asia. Over the last several years, he has successfully assisted many Asian companies in their technology transfers and licensing deals to and from the U.S., as well as with numerous regulatory submissions to the U.S. FDA.

Dr. Keith Chan obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota in 1980.

Back to About Us